Literature DB >> 26988874

Assessment of RNA carrier function in peptide amphiphiles derived from the HIV fusion peptide.

Yaowalak Pratumyot1, Oscar B Torres1, Dennis Bong2.   

Abstract

A small library of amphiphilic peptides has been evaluated for duplex RNA carrier function into A549 cells. We studied peptides in which a C-terminal 7-residue cationic domain is attached to a neutral/hydrophobic 23-residue domain that is based on the viral fusion peptide of HIV. We also examined peptides in which the cationic charge was evenly distributed throughout the peptide. Strikingly, subtle sequence variations in the hydrophobic domain that do not alter net hydrophobicity result in wide variation in RNA uptake. Additionally, cyclic cystine variants are much less active as RNA carriers than their open-chain cysteine analogs. With regard to electrostatic effects, we find that lysine is less effective than arginine in facilitating uptake, and that even distribution of cationic residues throughout the peptide sequence results in especially effective RNA carrier function. Overall, minor changes in peptide hydrophobicity, flexibility and charge distribution can significantly alter carrier function. We hypothesize this is due to altered properties of the peptide-RNA assembly rather than peptide secondary structure.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amphiphilic peptide; Carrier; Electrostatics; Nucleic acids; Transport

Mesh:

Substances:

Year:  2016        PMID: 26988874      PMCID: PMC4842095          DOI: 10.1016/j.peptides.2016.03.004

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  30 in total

1.  Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells.

Authors:  Federica Simeoni; May C Morris; Frederic Heitz; Gilles Divita
Journal:  Nucleic Acids Res       Date:  2003-06-01       Impact factor: 16.971

2.  A trimeric HIV-1 fusion peptide construct which does not self-associate in aqueous solution and which has 15-fold higher membrane fusion rate.

Authors:  Rong Yang; Mary Prorok; Francis J Castellino; David P Weliky
Journal:  J Am Chem Soc       Date:  2004-11-17       Impact factor: 15.419

3.  Fusion peptides and transmembrane domains of fusion proteins are characterized by different but specific structural properties.

Authors:  Katrin Weise; Jennifer Reed
Journal:  Chembiochem       Date:  2008-04-14       Impact factor: 3.164

4.  New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites.

Authors:  J M Parker; D Guo; R S Hodges
Journal:  Biochemistry       Date:  1986-09-23       Impact factor: 3.162

Review 5.  Antimicrobial peptides and viral fusion peptides: how different they are?

Authors:  P Joanne; P Nicolas; C El Amri
Journal:  Protein Pept Lett       Date:  2009       Impact factor: 1.890

6.  HIV fusion peptide and its cross-linked oligomers: efficient syntheses, significance of the trimer in fusion activity, correlation of beta strand conformation with membrane cholesterol, and proximity to lipid headgroups.

Authors:  Wei Qiang; David P Weliky
Journal:  Biochemistry       Date:  2009-01-20       Impact factor: 3.162

7.  Controlled fusion of synthetic lipid membrane vesicles.

Authors:  Mingming Ma; Dennis Bong
Journal:  Acc Chem Res       Date:  2013-07-23       Impact factor: 22.384

8.  Functional determinants of a synthetic vesicle fusion system.

Authors:  Yun Gong; Mingming Ma; Yumei Luo; Dennis Bong
Journal:  J Am Chem Soc       Date:  2008-04-11       Impact factor: 15.419

Review 9.  The road to therapeutic RNA interference (RNAi): Tackling the 800 pound siRNA delivery gorilla.

Authors:  Bryan R Meade; Steven F Dowdy
Journal:  Discov Med       Date:  2009-12       Impact factor: 2.970

10.  Mutational analysis of the fusion peptide of the human immunodeficiency virus type 1: identification of critical glycine residues.

Authors:  M D Delahunty; I Rhee; E O Freed; J S Bonifacino
Journal:  Virology       Date:  1996-04-01       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.